文献速递淋巴瘤

克隆多样性预测慢性淋巴细胞白血病的不良结局

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2018-07-23

该研究对643例慢性淋巴细胞白血病(CLL)患者进行靶向二代测序,分析七个反复突变驱动基因的克隆组成及预后价值,发现治疗患者中TP53和SF3B1突变频率更高、亚克隆突变数更多。进一步对50例进展者和17例匹配非进展者用404基因测序 panel 评估克隆演化,进展者初诊时携带更多突变,特定基因突变与进展风险增减相关,Notch和MAP激酶通路突变在进展者中富集。

要点

  • 治疗患者TP53突变频率35% vs 12%(p<0.001),SF3B1突变20% vs 11%(p<0.05)。
  • 进展者初诊时突变数2.5 vs 1(p<0.0001),多于非进展者。
  • SF3B1、ATM、FBXW7突变与进展风险增加相关,AXIN1、MYD88突变与进展风险降低相关。

核心结论

  • 特定基因组改变和亚克隆多样性与CLL疾病进展及疾病持续相关,并识别出新的反复突变基因及相关结局。

研究设计与样本

  • 对643例CLL患者使用靶向二代测序分析七个反复突变驱动基因的克隆组成及预后价值。
  • 对50例进展者和17例匹配的非进展者使用404基因测序 panel 进行克隆演化的深入评估。

主要发现

  • 治疗患者中TP53突变频率35% vs 12%(p<0.001),SF3B1突变频率20% vs 11%(p<0.05),(亚)克隆突变数增加(p<0.0001)。
  • 进展者初诊时携带更多突变(2.5 vs 1,p<0.0001)。
  • SF3B1、ATM和FBXW7突变与进展风险增加相关,AXIN1和MYD88突变与进展风险降低相关。
  • Notch和MAP激酶通路等特定信号通路突变在进展者中相对非进展者富集。
  • 识别出AXIN1、SDHA、SUZ12和FOXO3等新的突变基因。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genomic analyses of chronic lymphocytic leukemia (CLL) identified somatic mutations and associations of clonal diversity with adverse outcomes. Clonal evolution likely has therapeutic implications but its dynamic is less well studied. We studied clonal composition and prognostic value of seven recurrently mutated driver genes using targeted next-generation sequencing in 643 CLL patients and found higher frequencies of mutations in TP53 (35 vs. 12%, p < 0.001) and SF3B1 (20 vs. 11%, p < 0.05) and increased number of (sub)clonal (p < 0.0001) mutations in treated patients. We next performed an in-depth evaluation of clonal evolution on untreated CLL patients (50 "progressors" and 17 matched "non-progressors") using a 404 gene-sequencing panel and identified novel mutated genes such as AXIN1, SDHA, SUZ12, and FOXO3. Progressors carried more mutations at initial presentation (2.5 vs. 1, p < 0.0001). Mutations in specific genes were associated with increased (SF3B1, ATM, and FBXW7) or decreased progression risk (AXIN1 and MYD88). Mutations affecting specific signaling pathways, such as Notch and MAP kinase pathway were enriched in progressive relative to non-progressive patients. These data extend earlier findings that specific genomic alterations and diversity of subclones are associated with disease progression and persistence of disease in CLL and identify novel recurrently mutated genes and associated outcomes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Leeksma AC, Taylor J, Wu B, et al. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia. 2018. PMID: 30038380. doi:10.1038/s41375-018-0215-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。